-
Innovation Ranking
Innovation Ranking – Toyo Ink SC Holdings Co Ltd
Toyo Ink SC Holdings Co Ltd (Toyo Ink) is a chemical manufacturer and distributor. The company provides services such as printing and information business, a packaging business, polymer and coating business, color and functional materials business and others. Toyo Ink’s product portfolio includes printing inks, industrial chemicals, offset inks, inkjet inks, gravure inks, gravure solvents, screen inks, flexographic inks, can coatings, adhesives, pigments, high function pigments and plastic colorants, and printing equipment, and systems. The company has operations in France,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SC-291 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SC-291 in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Graves' Ophthalmopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Efgartigimod Alfa + Hyaluronidase (human Recombinant))...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Efgartigimod Alfa + Hyaluronidase (human Recombinant)) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Efgartigimod Alfa +...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Methylnaltrexone Bromide in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Methylnaltrexone Bromide in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Methylnaltrexone Bromide in Head And...
-
Product Insights
NewNevro Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Nevro Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Nevro Corp (Nevro) is a medical device company, which is engaged in developing novel products that advance the quality of life for people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacological neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Metastatic Transitional (Urothelial) Tract Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Leiomyosarcoma Drug Details: Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Metastatic Biliary Tract Cancer Drug Details: Lurbinectedin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Neuroendocrine Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lurbinectedin in Neuroendocrine Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Neuroendocrine Carcinoma Drug Details: Lurbinectedin (Zepzelca) is a synthetic...